Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NuCana PLC Sponsored ADR (NCNA : NSDQ)

• Company Description    NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $0.85 Daily Weekly Monthly 20 Day Moving Average: 33,352 shares Shares Outstanding: 52.37 (millions) Market Capitalization: $44.52 (millions) Beta: 1.23 52 Week High: $2.24 52 Week Low: $0.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.06% 15.51% 12 Week -35.70% -40.31% Year To Date 28.79% 17.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 Lochside Way - Edinburgh,X0 EH12 9DT GBR ph: 44-0-13-1357-1111 fax: - chris.brinzey@westwicke.com http://www.nucana.com

• General Corporate Information    Officers Hugh Griffith - Chief Executive Officer Andrew Kay - Chairman Donald Munoz - Chief Financial Officer Martin Mellish - Director Cyrille Leperlier - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67022C106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/16/23 Share - Related Items Shares Outstanding: 52.37 Most Recent Split Date: (:1) Beta: 1.23 Market Capitalization: $44.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/16/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.15 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 14.29% vs. Previous Quarter: 47.06% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -68.84 12/31/22 - -60.80 09/30/22 - -52.95 ROA 03/31/23 - -50.88 12/31/22 - -47.34 09/30/22 - -43.49 Current Ratio 03/31/23 - 2.73 12/31/22 - 2.84 09/30/22 - 4.04 Quick Ratio 03/31/23 - 2.73 12/31/22 - 2.84 09/30/22 - 4.04 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 0.74 12/31/22 - 0.91 09/30/22 - 1.19 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©